Director of Cloud Infrastructure, Freenome
$19.7-304k
+ pre-IPO Equity + Bonus
Biological analysis platform for cancer
Open for applications
Biological analysis platform for cancer
501-1000 employees
Open for applications
$19.7-304k
+ pre-IPO Equity + Bonus
501-1000 employees
Company mission
To reinvent disease management through early detection and precision intervention.
Jump to section
Company mission
To reinvent disease management through early detection and precision intervention.
Our take
Freenome is a biotechnology company offering a biological analysis platform that uses molecular biology and machine learning to detect cancer with a routine blood draw. The platform trains on thousands of cancer-positive blood samples to recognise disease-associated patterns and help detect early-stage cancer, allowing clinicians to optimise treatments.
The company specialises in advanced computational biology, using machine learning to detect patterns among billions of circulating cell-free biomarkers. Freenome continues to focus on the development of its colorectal cancer test, potentially helping the 45 million people not currently up-to-date on colorectal cancer screening guidelines in the United States.
Following its 2022 funding round, the company surpassed the $1 billion funding mark. Freenome is set to accelerate the development of its platform, testing for additional cancers and furthering its blood test detection technology. It's also forming partnerships for R&D purposes, joining forces with health firms such as Geisinger to provide real world data that could help it detect multiple cancers.
Steph
Company Specialist at Welcome to the Jungle
Benefits
- Pre-IPO equity
- Flexible PTO (exempt) and generous PTO (non-exempt)
- Comprehensive health coverage, including medical, dental, and vision
- Wellness and mental health resources, including Employee Assistance Programs (EAPs), Paid maternity and paternity leave
- 401(k) plan
- Plus, a variety of other perks, including pre-tax commuter benefits, two paid volunteer days per year, pet insurance, and additional discounts
Funding (last 2 of 7 rounds)
Feb 2024
$254m
LATE VC
Dec 2021
$300m
SERIES D
Total funding: $1.1bn
This company has top investors
Leadership
Riley Ennis
(CPO)Studied at Yale, Johns Hopkins and Dartmouth. Was a Thiel Fellow and co-founded Immudicon and Oncolinx.
Articles
Jobs (4)
Software Engineering
Marketing